Skip to main content
Premium Trial:

Request an Annual Quote

New England Biolabs, Bluebee Partner for Sequencing Data Analysis

NEW YORK (GenomeWeb) – New England Biolabs and Netherlands-based bioinformatics firm Bluebee have formed a partnership to provide data processing of sequencing technology.

The partnership will allow customers using the NEBNext Direct workflow to rapidly analyze, store, and manage large amounts of sequencing data using a pipeline designed by Bluebee to maximize the benefits of the target enrichment technology. NEBNext Direct is a workflow that hybridizes baits directly to genomic DNA without the need for upfront library preparation and incorporates a unique molecule index to improve accuracy of predictions of variant allele frequencies.

NEBNext Direct has also been added by the firm into the NEBNext Direct Cancer HotSpot Panel, which provides a one-day, single-tube workflow combining enrichment with library preparation and enriching critical regions within 50 commonly studied genes known to be associated with cancer.

"Having the ability to execute complex analytical procedures through a simple user interface ensures our customers reliable and accurate data, providing them more time to analyze and interpret results," Andrew Barry, product marketing manager at NEB, said in a statement.

The Bluebee platform supports users in clinical diagnostics, therapeutics, and research with analytics for genomic medicine through a private cloud service. It centralizes and manages genomics data processes and storage, with multi-layered security to meet both organizational and regulatory data protection requirements.

Bluebee raised €10 million ($11.6 million) in a Series A financing round in 2016, and has since formed partnerships with firms such as GATC Biotech, Lexogen, MediSapiens, Pacific Biosciences, and Agendia.  

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.